CBIO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Crescent Biopharma advances its clinical pipeline, enrolling patients in standard chemotherapy combination cohorts of the global Phase 1/2 ASCEND trial of CR-001 and launching additional antibody-drug conjugate combination studiesOct 15, 2026
- Crescent Biopharma receives FDA clearance for the IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC for solid tumorsOct 5, 2026
- Crescent Biopharma dosed the first patient in the Phase 1/2 ASCEND trial of CR-001 for advanced solid tumorsFeb 18, 2026
- Crescent Biopharma receives IND clearances for CR-001 PD‑1 x VEGF bispecific antibody and CR-003 ITGB6‑targeted ADC to treat solid tumorsJan 5, 2026
- Kelun-Biotech and Crescent Biopharma announce strategic partnership for novel oncology therapeutics development and commercializationDec 4, 2025